Study finds untreated vision loss and high cholesterol are linked to increased dementia risk

News
Article

As many as 14 risk factors have now been found for dementia.

Wife consoles husband suffering from memory loss Image credit: AdobeStock/comzeal

Image credit: AdobeStock/comzeal

A new report in The Lancet identified untreated vision loss and high cholesterol as risk factors in the development of dementia.1

The Commission has now identified a total of 14 risk factors, with the latest ones, vision loss and high cholesterol, added to the list.

“Overall,” the Commission commented, “around 45% of cases of dementia are potentially preventable by addressing the 14 modifiable risk factors at different stages during the life course.”

Notably, these risk factors can be affected by changes in lifestyle. The factors mentioned previously that research has uncovered also can be addressed.

“Evidence is increasing and is now stronger than before that tackling the many risk factors for dementia that we modeled previously (ie, less education, hearing loss, hypertension, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol consumption [ie, >21 UK units, equivalent to >12 US units], traumatic brain injury, air pollution, and social isolation),” according to the Commission’s report.

They underscored the importance of lifestyle interventions. “By incorporating these potentially reversible risk factors from different phases of the life-span and not just old age, we are able to propose a novel life-course model of risk, from which population attributable fractions have been derived to show the possible effect on future incidence of successful elimination of the most potent factors. We have brought together all this evidence and have calculated that more than a third of dementia cases might theoretically be preventable.”

Dementia has a huge societal impact. With about 47 million people living with dementia, the costs are staggering. “The 2015 global cost of dementia was estimated to be $818 billion in US dollars, and this figure will continue to increase as the number of people with dementia rises. Nearly 85% of costs are related to family and social, rather than medical, care. It might be that new medical care in the future, including public health measures, could replace and possibly reduce some of this cost,” the Commission commented.

The bottom-line message is that dementia is not an inevitable consequence of aging.

The key messages of the report are as follows:

  • The number of people with dementia is increasing globally, although the incidence in some countries has decreased.
  • Be ambitious about prevention. Recommended actions include active treatment of hypertension in middle-aged people 45–65 years and people older than 65 years without dementia. Interventions for other risk factors including more childhood education, exercise, maintaining social engagement, reducing smoking, and management of hearing loss, depression, diabetes, and obesity may delay/prevent a third of dementia cases.
  • Treat cognitive symptoms to maximize cognition. Alzheimer’s disease or dementia with Lewy bodies can be treated with cholinesterase inhibitors at all stages other than mild impairment, or memantine for severe dementia.
  • Individualize dementia care to include medical, social, and supportive care; this includes unique individual and cultural needs, preferences, and priorities and support for family carers.
  • Care for family carers are at high risk of depression. The Commission recommends these interventions to reduce depression and treat symptoms: STrAtegies for RelaTives (START) or Resources for Enhancing Alzheimer’s Caregiver Health intervention (REACH).
  • Plan for the future. This includes discussions about the future decision-making possibly by attorneys and the ability of clinicians to make different types of decisions at diagnosis.
  • Protect people with dementia against self-neglect, vulnerability (including exploitation), managing money, driving, or using weapons.
  • Manage neuropsychiatric symptoms that include agitation, low mood, or psychosis with psychologic, social, and environmental management; pharmacologic management is reserved for more severe symptoms.
  • End-of-life decisions. Professionals working in end-of-life care should consider if a patient has dementia to ensure that decisions are made about their care and treatment and needs and wishes.
  • Technology interventions can improve care delivery but should not replace social contact.
Reference:
  1. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024; published online July 31; DOI: https://doi.org/10.1016/S0140-6736(24)01296-0
Recent Videos
Optometrists reflect on their residency experiences and provide advice to current residents.
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
© 2024 MJH Life Sciences

All rights reserved.